The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1289
Olopatadine (Patanase) Nasal Spray
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Olopatadine 0.6% nasal spray (Patanase – Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥12 years old. An H1- antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin), another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.

DRUGS FOR ALLERGIC RHINITIS — A variety of oral and topical drugs are marketed for treatment of allergic rhinitis.1 An oral second-generation H1-antihistamine is often used for treatment of mild to moderate disease; loratadine (Claritin, and others), fexofenadine (Allegra, and others) and cetirizine (Zyrtec, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Olopatadine (Patanase) Nasal Spray
Article code: 1289c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian